Last week Verastem presented additional Copiktra data at the Leerinks Health Care Conference followed by a Q&A session by analysts. The webcast can be accessed here. In this article, I discuss the … [Read more...] about Can Verastem Shake the DownTrend?
Last fall, Verastem Oncology (NASDAQ: VSTM) received FDA-approval for its first drug, Copiktra, an oral monotherapy for the treatment of relapsed or refractory chronic lymphotic leukemia, small … [Read more...] about Verastem Oncology: Looking for a Port in the Storm
Lymphoma Patients Want and Need A Better Quality Of Life As a Lymphoma survivor, I can say unequivocally, that TO MUCH TIME is spent in the chemo wing, away from our families. Therefore, as … [Read more...] about (Nasdaq: VSTM) Verastem, Better Quality of Life? A Patients Perspective
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. Good Morning! We hope you all are enjoying your early morning trading! Today, three companies we … [Read more...] about Morning Update-Form 13G’s On Deck!
Leave a comment and click here to subscribe for MS article alerts and our newsletter! Overview January 10th, in an Amended 13G/A, Street Corp updated their reported holdings in VSTM to … [Read more...] about State Street Corp’s Amended 13G/A Reveals 11.53% Ownership of VSTM
01/09/2019 Leave a comment and click here to subscribe for MS article alerts and our newsletter! Verastem Oncology (Nasdaq: VSTM) is up 7.18% on trading at $4.33 on moderate volume of … [Read more...] about Wednesday Pre-market Movers
Leave a comment and click here to sub for MS article alerts and our newsletter Introduction Investors and watchers of VSTM were elated to receive positive news from the FDA in late September … [Read more...] about VSTM- A Reduced Risk Oncology Company
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
For months Verastem Oncology (VSTM) investors have been eagerly awaiting the FDA's decision on it's lead product Duvelisib; a PI3K-δ (delta) and PI3K-γ (gamma) inhibitor that was granted Orphan Drug … [Read more...] about VSTM Overaction to Black Box Label Creates Buying Opportunity